Showing 301-310 of 333 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Stem Cell-derived Islet Vascularized Extracellular Matrix Organoids for Enhanced Transplantation Success | University of Wisconsin-Madison (Board of Regents University of Wisconsin System) | Jon Odorico | Cures | 01-January-2024 to 31-December-2026 | $1,394,960.67 |
| Discovering early diagnostic markers of cardiovascular disease risk with lipidomics in a 30-year longitudinal prospective type 1 diabetes cohort | University of Wisconsin-Madison (Board of Regents University of Wisconsin System) | Judith Simcox | Improving Lives | 01-November-2022 to 31-October-2025 | $799,988.63 |
| ICAM-1 Knock Out Pluripotent Stem Cells for Hypoimmune Type 1 Diabetes Therapy | University of Wisconsin-Madison (Board of Regents University of Wisconsin System) | Matthew Brown | Cures | 01-April-2025 to 31-March-2027 | $699,998.53 |
| Immune-checkpoint engineered beta cells as treatment for T1D | UT Southwestern | Andrew Wang | Cures | 01-October-2023 to 30-September-2026 | $746,818.40 |
| Targeted delivery of therapeutics to islet beta cells for preventing and treating diabetes | UT Southwestern | Juanzhu Yan | Cures | 01-March-2025 to 29-February-2028 | $285,000.00 |
| Nf2/Merlin Is a Key Mediator of Pancreatic Morphogenesis and Endocrine Differentiation | UT Southwestern | Neha Ahuja | Cures | 01-March-2023 to 28-February-2026 | $214,356.00 |
| Developing fusion therapeutics to selectively target beta cell surface receptors for treating T1D | UT Southwestern | Wen-hong Li | Cures | 01-July-2022 to 30-June-2025 | $900,000.00 |
| Harnessing zinc-tropic agents for targeted delivery of therapeutics to islet beta cells for preventing or treating T1D | UT Southwestern | Wen-hong Li | Cures | 01-August-2022 to 31-October-2025 | $900,000.00 |
| Development of Allosteric G6PC1 Partial Inhibitors | Vanderbilt University | Richard O'Brien | Improving Lives | 01-October-2023 to 08-August-2026 | $549,940.00 |
| Determination of autoreactive B lymphocyte development by ROS in T1D | Vanderbilt University Medical Center (VUMC) | Christopher Wilson | Cures | 01-July-2023 to 30-June-2026 | $234,766.00 |